Tango Therapeutics, Inc.(TNGX)Earnings, Financials & Key RatiosTango Therapeutics, Inc. (TNGX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on a single counterparty for revenue and its persistent negative free cash flow, which resulted in a $44.4 million outflow in 2026Q1, present significant risks to long-term shareholder value.
Tango Therapeutics, Inc. (TNGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Tango Therapeutics, Inc. (TNGX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.32vs $0.31-2.0% | —vs $578,091 |
| Q2 2026 | Mar 5, 2026 | $0.29vs $0.31+6.5% | —vs $500,400 |
| Q4 2025 | Nov 4, 2025 | $0.13vs $0.01+1200.0% | $54Mvs $556,000+9578.2% |
| Q3 2025 | Aug 5, 2025 | $0.35vs $0.35+0.0% | $3Mvs $6M-50.3% |
Recent stock market news and headlines for Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with pancreatic cancer.
Key metrics vs top competitors for Tango Therapeutics, Inc. (TNGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.94 | $3.48B | -34.41 | 48.29% | -162.85% | -37.23% | — | |
| $189.99 | $40.39B | -31.93 | — | — | -83.22% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $15.49 | $1.99B | 7.48 | 20.38% | 99.97% | 64.48% | — | |
| $1.21 | $64.26M | -0.81 | — | — | -68.98% | — |
Tango Therapeutics, Inc. (TNGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Tango Therapeutics, Inc. (TNGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
May 8, 2026·SEC
Apr 15, 2026·SEC
Get notified when TNGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tango Therapeutics, Inc. (TNGX) stock FAQ — growth, dividends, profitability & financials explained
Tango Therapeutics, Inc. (TNGX) reported $57.0M in revenue for fiscal year 2025. This represents a 131% increase from $24.6M in 2019.
Tango Therapeutics, Inc. (TNGX) grew revenue by 48.3% over the past year. This is strong growth.
Tango Therapeutics, Inc. (TNGX) reported a net loss of $107.2M for fiscal year 2025.
Tango Therapeutics, Inc. (TNGX) has a return on equity (ROE) of -37.2%. Negative ROE indicates the company is unprofitable.
Tango Therapeutics, Inc. (TNGX) had negative free cash flow of $142.5M in fiscal year 2025, likely due to heavy capital investments.
